These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30859149)

  • 1. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.
    Mayo MJ; Pockros PJ; Jones D; Bowlus CL; Levy C; Patanwala I; Bacon B; Luketic V; Vuppalanchi R; Medendorp S; Dorenbaum A; Kennedy C; Novak P; Gu J; Apostol G; Hirschfield GM
    Hepatol Commun; 2019 Mar; 3(3):365-381. PubMed ID: 30859149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Miethke AG; Moukarzel A; Porta G; Covarrubias Esquer J; Czubkowski P; Ordonez F; Mosca A; Aqul AA; Squires RH; Sokal E; D'Agostino D; Baumann U; D'Antiga L; Kasi N; Laborde N; Arikan C; Lin CH; Gilmour S; Mittal N; Chiou FK; Horslen SP; Huber WD; Jaecklin T; Nunes T; Lascau A; Longpre L; Mogul DB; Garner W; Vig P; Hupertz VF; Gonzalez-Peralta RP; Ekong U; Hartley J; Laverdure N; Ovchinsky N; Thompson RJ
    Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):620-631. PubMed ID: 38723644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
    Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Gonzales E; Hardikar W; Stormon M; Baker A; Hierro L; Gliwicz D; Lacaille F; Lachaux A; Sturm E; Setchell KDR; Kennedy C; Dorenbaum A; Steinmetz J; Desai NK; Wardle AJ; Garner W; Vig P; Jaecklin T; Sokal EM; Jacquemin E
    Lancet; 2021 Oct; 398(10311):1581-1592. PubMed ID: 34755627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
    Bowlus CL; Eksteen B; Cheung AC; Thorburn D; Moylan CA; Pockros PJ; Forman LM; Dorenbaum A; Hirschfield GM; Kennedy C; Jaecklin T; McKibben A; Chien E; Baek M; Vig P; Levy C
    Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37184523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
    von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
    J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome.
    Shneider BL; Spino C; Kamath BM; Magee JC; Bass LM; Setchell KD; Miethke A; Molleston JP; Mack CL; Squires RH; Murray KF; Loomes KM; Rosenthal P; Karpen SJ; Leung DH; Guthery SL; Thomas D; Sherker AH; Sokol RJ;
    Hepatol Commun; 2018 Oct; 2(10):1184-1198. PubMed ID: 30288474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
    Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
    JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
    Levy C; Kendrick S; Bowlus CL; Tanaka A; Jones D; Kremer AE; Mayo MJ; Haque N; von Maltzahn R; Allinder M; Swift B; McLaughlin MM; Hirschfield GM;
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1902-1912.e13. PubMed ID: 36343847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    Bowlus CL; Galambos MR; Aspinall RJ; Hirschfield GM; Jones DEJ; Dörffel Y; Gordon SC; Harrison SA; Kremer AE; Mayo MJ; Thuluvath PJ; Levy C; Swain MG; Neff GW; Sheridan DA; Stanca CM; Berg CP; Goel A; Shiffman ML; Vierling JM; Boudes P; Steinberg A; Choi YJ; McWherter CA
    J Hepatol; 2022 Aug; 77(2):353-364. PubMed ID: 35367282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials.
    Himes R; Rosenthal P; Dilwali N; Smith K; Venick R; Gonzalez-Peralta RP
    J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):506-513. PubMed ID: 38334237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis.
    Xu C; Yue R; Lv X; Wang S; Du M
    Front Pharmacol; 2022; 13():835991. PubMed ID: 36339545
    [No Abstract]   [Full Text] [Related]  

  • 13. Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life.
    Kamath BM; Goldstein A; Howard R; Garner W; Vig P; Marden JR; Billmyer E; Anderson A; Kirson N; Jacquemin E; Gonzales E
    J Pediatr; 2023 Jan; 252():68-75.e5. PubMed ID: 36096175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hansen BE; Vandriel SM; Vig P; Garner W; Mogul DB; Loomes KM; Piccoli DA; Rand EB; Jankowska I; Czubkowski P; Gliwicz-Miedzińska D; Gonzales EM; Jacquemin E; Bouligand J; D'Antiga L; Nicastro E; Arnell H; Fischler B; Sokal É; Demaret T; Siew S; Stormon M; Karpen SJ; Romero R; Ebel NH; Feinstein JA; Roberts AJ; Evans HM; Sundaram SS; Chaidez A; Hardikar W; Shankar S; Fischer RT; Lacaille F; Debray D; Lin HC; Jensen MK; Jaramillo C; Karthikeyan P; Indolfi G; Verkade HJ; Larson-Nath C; Quiros-Tejeira RE; Valentino PL; Rogalidou M; Dezsőfi A; Squires JE; Schwarz K; Calvo PL; Bernabeu JQ; Zizzo AN; Nebbia G; Bulut P; Santos-Silva E; Fawaz R; Nastasio S; Karnsakul W; Tamara ML; Busoms CM; Kelly DA; Sandahl TD; Jimenez-Rivera C; Banales JM; Mujawar Q; Li LT; She H; Wang JS; Kim KM; Oh SH; Sanchez MC; Cavalieri ML; Lee WS; Hajinicolaou C; Lertudomphonwanit C; Waisbourd-Zinman O; Arikan C; Alam S; Carvalho E; Melere M; Eshun J; Önal Z; Desai DM; Wiecek S; Pinto RB; Wolters VM; Garcia J; Beretta M; Kerkar N; Brecelj J; Rock N; Lurz E; Blondet N; Shah U; Thompson RJ; Kamath BM;
    Hepatology; 2024 Jun; 79(6):1279-1292. PubMed ID: 38146932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus.
    Hegade VS; Pechlivanis A; McDonald JAK; Rees D; Corrigan M; Hirschfield GM; Taylor-Robinson SD; Holmes E; Marchesi JR; Kendrick S; Jones DE
    Liver Int; 2019 May; 39(5):967-975. PubMed ID: 30735608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for treating cholestasis in pregnancy.
    Burrows RF; Clavisi O; Burrows E
    Cochrane Database Syst Rev; 2001; (4):CD000493. PubMed ID: 11687082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
    Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Itching to Know: Role of Fibrates in PBC.
    Levy C; Lindor KD
    Am J Gastroenterol; 2018 Jan; 113(1):56-57. PubMed ID: 29311728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.